Bimagrumab is a monoclonal antibody targeting type II activin receptors. In a randomized trial, bimagrumab combined with semaglutide led to up to 17.8 kg weight reduction, surpassing the effects of semaglutide alone (up to 14.2 kg). Notably, the combination preserved lean mass while reducing visceral fat, highlighting its potential for effective obesity management.
- Steven B. Heymsfield
- Louis J. Aronne
- Kenneth M. Attie
